France Small Animal Imaging (in vivo) Market

France Small Animal Imaging (in vivo) Market Size Insights Forecasts to 2035

• The France Small Animal Imaging (in vivo) Market Size Was Estimated at USD 50.00 Million in 2024
• The France Small Animal Imaging (in vivo) Market Size is Expected to Grow at a CAGR of Around 9.01% from 2025 to 2035
• The France Small Animal Imaging (in vivo) Market Size is Expected to Reach USD 129.1 Million by 2035

According to a Research Report Published by Decisions Advisors & Consulting, The France Small Animal Imaging (in vivo) Market Size is anticipated to Reach USD 129.1 Million by 2035, Growing at a CAGR of 9.01% from 2025 to 2035. The France small animal imaging (in vivo) market is driven by rising biomedical and pharmaceutical R&D, increasing preclinical and translational research activities, and growing adoption of advanced non-invasive imaging technologies such as micro-CT, MRI, PET, and optical imaging. Strong academic research infrastructure, expanding CRO involvement, and continuous technological advancements further support market growth.

 

Market Overview

The France small animal imaging (in vivo) market refers to the market for advanced imaging systems and related software used to non-invasively visualize, monitor, and analyze biological processes in live small animal models, such as mice and rats, within France. These imaging technologies, including optical imaging, micro-CT, micro-MRI, PET, SPECT, and ultrasound, are primarily used in preclinical research, drug discovery, disease modeling, and translational studies across academic institutions, pharmaceutical companies, and contract research organizations.

 

France’s adoption of the small animal imaging (in vivo) market is strongly linked to its population health needs and intensive biomedical research activity. The country faces a high burden of chronic and complex diseases such as cancer, neurological disorders, cardiovascular diseases, and immune-related conditions, which require advanced preclinical studies before human trials. France is among Europe’s leading nations in life-science research, with thousands of ongoing preclinical studies using rodent models to evaluate drug efficacy, disease progression, and biomarker response. Small animal imaging enables non-invasive, real-time monitoring, reduces animal usage, and accelerates translational research, making it essential for pharmaceutical companies, biotech firms, CROs, and academic institutions.

 

Government support significantly strengthens market adoption. France invests over €60 billion annually in research and development, with health and life sciences as priority areas. Major initiatives such as the France 2030 plan (€54 billion) and funding programs through Inserm, ANR, and national imaging networks like France-BioImaging and France Life Imaging actively support advanced imaging infrastructure, including in vivo preclinical imaging. These policies and investments highlight the strategic importance of small animal imaging in strengthening France’s drug development pipeline, innovation capacity, and global competitiveness in biomedical research.

 

Report Coverage

This research report categorizes the market for the France small animal imaging (in vivo) market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France small animal imaging (in vivo) market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France small animal imaging (in vivo) market.

 

Driving Factors

The France small animal imaging (in vivo) market is driven by increasing preclinical and translational research, rising pharmaceutical and biotechnology R&D investments, and growing demand for non-invasive, high-resolution imaging technologies. Strong government support for life-science research, expanding CRO activities, and continuous technological advancements further accelerate market adoption.

 

Restraining Factors

The France small animal imaging (in vivo) market faces restraining factors such as the high cost of advanced imaging systems and their maintenance, which limits adoption among smaller research facilities. Strict regulatory and ethical guidelines on animal research, a shortage of skilled imaging professionals, and the complexity of operating multimodal imaging platforms also constrain market growth.

 

Market Segmentation

The France small animal imaging (in vivo) market share is classified into modality and application.

• The optical imaging systems segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France small animal imaging (in vivo) market is segmented by modality into nuclear imaging, optical imaging systems, micro-magnetic resonance imaging, and others. Among these, the optical imaging systems segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The optical imaging systems segment is growing because of their high sensitivity, lower cost, ease of use, and ability to enable real-time, non-invasive imaging, making them widely preferred for preclinical and molecular research in France.

 

• The biodistribution studies segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The France small animal imaging (in vivo) market is segmented by application into biodistribution studies, epigenetics, monitoring drug treatment response, cancer cell detection, biomarkers, longitudinal studies, and others. Among these, the biodistribution studies segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The biodistribution studies segment is growing because of the increasing need to track drug and tracer distribution, metabolism, and accumulation in real time during preclinical research. Rising pharmaceutical and biotechnology R&D activities, along with the demand for accurate safety, efficacy, and dose-optimization data, are driving strong adoption of small animal imaging for biodistribution studies in France.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France small animal imaging (in vivo) market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• PerkinElmer, Inc.
• Bruker Corporation
• FUJIFILM Holdings Corporation
• Mediso Medical Imaging Systems
• Aspect Imaging Ltd.
• Thermo Fisher Scientific Inc.
• Siemens Healthineers
• Miltenyi Biotec GmbH
• MILabs B.V.
• MR Solutions Ltd.
• TriFoil Imaging
• LI-COR Biosciences
• Inviscan Imaging Systems
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the France small animal imaging (in vivo) market based on the below-mentioned segments:

 

France Small Animal Imaging (in vivo) Market, By Modality

• Nuclear Imaging
• Optical Imaging Systems
• Micro-magnetic Resonance Imaging
• Others

 

France Small Animal Imaging (in vivo) Market, By Application

• Biodistribution Studies
• Epigenetics
• Monitoring Drug Treatment Response
• Cancer Cell Detection
• Biomarkers
• Longitudinal Studies
• Others

 

FAQ’s

1. What is the France small animal imaging (in vivo) market size in 2024?

The France small animal imaging (in vivo) market size was estimated at USD 50.00 million in 2024.

 

2. What is the projected market size of the France small animal imaging (in vivo) market by 2035?

The France small animal imaging (in vivo) market size is expected to reach USD 129.1 million by 2035.

 

3. What is the CAGR of the France small animal imaging (in vivo) market?

The France small animal imaging (in vivo) market size is expected to grow at a CAGR of around 9.01% from 2024 to 2035.

 

4. What are the key growth drivers of the France small animal imaging (in vivo) market?

The France small animal imaging (in vivo) market is driven by rising biomedical and pharmaceutical R&D, increasing preclinical and translational research activities, and growing adoption of advanced non-invasive imaging technologies such as micro-CT, MRI, PET, and optical imaging.

 

5. Which application segment dominated the market in 2024?

The biodistribution studies segment dominated the market in 2024.

 

6. What segments are covered in the France small animal imaging (in vivo) market report?

The France small animal imaging (in vivo) market is segmented on the basis of modality and application.

 

7. Who are the key players in the France small animal imaging (in vivo) market?

Key companies include PerkinElmer, Inc., Bruker Corporation, FUJIFILM Holdings Corporation, Mediso Medical Imaging Systems, Aspect Imaging Ltd., Thermo Fisher Scientific Inc., Siemens Healthineers, Miltenyi Biotec GmbH, MILabs B.V., MR Solutions Ltd., TriFoil Imaging, LI-COR Biosciences, Inviscan Imaging Systems, and others.

 

8. Who are the target audiences for this market report?

The report targets market players, investors, end-users, government authorities, consulting and research firms, venture capitalists, and value-added resellers (VARs).